Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-Il-23 Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Subjects
Basic and Clinical Pharmacology and Toxicology - United States
doi 10.1111/bcpt.13001
Full Text
Open PDFAbstract
Available in full text
Date
April 20, 2018
Authors
Publisher
Wiley